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Abstract
Background and Objective Chronic diseases are associ-
ated with pathophysiological changes that could have
profound impacts on drug pharmacokinetic behaviour, with
a potential need to modify the administered drug therapy. It
is important to acknowledge that most patients with
chronic illnesses do not have a single, predominant con-
dition but suffer from multiple comorbidities. The rapid
advancement in physiologically based pharmacokinetic
(PBPK) modelling, as well as the increasing quantitative
knowledge of disease-related pathophysiological changes,
facilitate building of drug–disease models. However, there
are only a few published examples of PBPK models in-
corporating the pathophysiological changes that occur with
chronic diseases. The objective of this study was to develop
PBPK models that incorporate the haemodynamic changes
in hepatic and renal blood flows occurring in chronic heart
failure (CHF) and to evaluate these changes in adults and
children, using carvedilol as a model drug.
Methods After a comprehensive literature search to select
the model input parameters, two PBPK models were
developed. Model 1 was based on human liver and in-
testinal microsome clearances, and model 2 was based on
clearance by specific cytochrome P450 enzymes. After
evaluation of both models in healthy adults, the reduced
hepatic and renal blood flows were incorporated into the
developed models to predict carvedilol exposure in the
adult CHF population. The adult carvedilol models were
scaled down to children by using Simcyp (Simcyp Ltd,
Sheffield, UK). In order to show the impact of reduced
organ blood flows on carvedilol disposition, the predictions
in the CHF population were made with and without re-
ductions in organ blood flows.
Results The predictions made by both models in healthy
adults were comparable and within the 2-fold error range.
In adults with CHF, the mean observed/predicted ratio
[ratio(Obs/Pred)] for oral clearance (CL/F) without reductions
in organ blood flows was outside the 2-fold error range,
i.e. 0.34 (95 % confidence interval [CI] 0.31–0.37), with
use of both models. The mean CL/F ratio(Obs/Pred) values
after incorporation of reduced organ blood flows were 1.0
(95 % CI 0.92–1.08) and 0.95 (95 % CI 0.88–1.03) with
use of models 1 and 2, respectively. The mean ratio(Obs/
Pred) values for the pharmacokinetic parameters were not
improved after incorporation of reduced blood flows in
paediatric patients, except in those above 17 years of age,
who were categorized according to the New York Heart
Association classification of CHF, where the CL/F ra-
tio(Obs/Pred) values in two patients were closer to unity.
Conclusion There was a strong connection between a
decrease in hepatic clearance of carvedilol and an increase
in the severity of CHF, especially in adults and in paedi-
atric patients above 17 years of age. The incorporated re-
ductions in hepatic and renal blood flows occurring in
moderate and severe CHF patients resulted in improved
predictions of carvedilol exposure. The developed models
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can be extended to predict exposures of drugs with high
hepatic extraction in the CHF population.
Key Points
Reductions in hepatic blood flow can significantly
affect the first-pass and systemic hepatic metabolism,
the bioavailability, and thus the total exposure of
drugs with high hepatic extraction ratios. For oral
administration, the total effect of these changes on
the exposure is more complex, since any changes in
reduced systemic clearance (CL/F) will be
compensated for by reduced bioavailability
(expected from higher hepatic extraction during the
first pass).
In chronic heart failure (CHF), a decrease in the CL/
F of carvedilol can be modelled by incorporation of
hepatic and renal blood flow changes occurring in
this disease, using a physiologically based
pharmacokinetic (PBPK) drug–disease model.
The incorporation of reduced hepatic and renal blood
flows into the presented PBPK models caused a
significant improvement in prediction of carvedilol
exposure in adult CHF patients, but with regard to
paediatric predictions, the improvements were seen
only in adolescents categorized according to the New
York Heart Association classification of CHF with
available pharmacokinetic data sets.
1 Introduction
Chronic diseases are associated with pathophysiological
changes that could have profound impacts on the phar-
macokinetic behaviour of drugs, with a potential need to
modify the administered drug therapy [1]. It is important to
acknowledge that most patients with chronic illnesses do
not have a single, predominant condition but suffer from
multiple comorbidities. The rapid advancement in physio-
logically based pharmacokinetic (PBPK) modelling, as
well as the increasing quantitative knowledge of disease-
related pathophysiological changes, facilitate building of
drug–disease models that can incorporate these changes to
predict their pharmacokinetic impact [2–8]. A PBPK model
that is modified according to the pathophysiology of a
disease could be extended, after its evaluation, to a wide
variety of drugs because of its mechanistic nature. An
additional gain can be further obtained if an extrapolation
from adult patients to special populations, e.g. children,
occurs.
However, despite the clinical significance, there are only
a few published examples of PBPK models incorporating
pathophysiological changes occurring with chronic dis-
eases [2–6]. Interestingly, to date, there has been no pub-
lished report of a drug–disease PBPK model evaluated for
predicting drug exposure in chronic heart failure (CHF)
adult and paediatric patients after incorporation of reduc-
tions in organ blood flows, despite the high prevalence and
the clinical importance of this disease. Instead, there are
some published PBPK models that have explored drug
pharmacokinetics in liver cirrhosis [2, 6], in chronic kidney
disease [3, 5, 8] and in patients with low cardiac output
syndrome undergoing cardiac surgery [4]. In CHF, there is
a gradual decrease in hepatic blood flow (QH) with in-
creasing severity of the disease, which has previously been
quantified in adults [9]. Development and evaluation of a
PBPK model that can incorporate the relevant hemody-
namic changes seen in CHF and that can quantify the im-
pact of those change could be of great use. This is
particularly true for drugs with high hepatic extraction ra-
tios, as these are most vulnerable to QH changes, resulting
in a significant effect on their clearance [10]. Under in-
travenous administration, the change in clearance will lead
to a direct change in drug exposure, while in the case of
oral administration, the effect of clearance changes on
exposure is more complex, as it is confounded and partly
compensated by the change in bioavailability.
In light of this information, and in order to evaluate a
PBPK CHF model with incorporated organ blood flow
changes, a model drug being used clinically in CHF with
high hepatic extraction was searched. Carvedilol, a third-
generation beta-blocker used in the treatment of various
cardiovascular disorders, undergoes extensive first-pass
metabolism with a high hepatic extraction ratio (0.7) and
absolute oral bioavailability of 22–24 % [11–14]. Because
of its high hepatic extraction and the availability of ob-
served clinical data in both adult and paediatric populations
[13, 15–18], carvedilol could serve as a model drug to
demonstrate if a PBPK disease model could accurately
predict the pharmacokinetic changes occurring in CHF.
The main objective of this study was to develop PBPK
models that incorporate the hemodynamic changes in hep-
atic and renal blood flows occurring in CHF, and to evaluate
it in adults and children, using carvedilol as a model drug.
2 Methods
2.1 Modelling Software and Strategy for Model-
Building
Simcyp Simulator version 13.1 (Simcyp Ltd, Sheffield,
UK) was used to provide the general structure of the
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developed PBPK models. Simcyp is a population-based
PBPK simulator used for bottom-up mechanistic drug
modelling of absorption, distribution, metabolism and
elimination (ADME). This software combines in vitro and
in vivo data on drug absorption, distribution and elimina-
tion with the physicochemical properties of the drug, in
addition to incorporating anatomical and physiological
data, to simulate the systemic exposure to the drug in
virtual healthy and diseased populations [19].
In the presented work, two PBPK models that differed
only in terms of the assigned clearance inputs were de-
veloped: model 1, with in vitro intrinsic clearance (CLint)
values based on human liver and intestinal microsomes
(HLM and HIM); and model 2, based on cytochrome P450
(CYP) enzyme clearances. The choice of presenting both
models was made because fewer assumptions were made
with model 1; however, model 2 can offer an additional
gain of information in the future by allowing the user to
incorporate information on genetic polymorphisms of the
metabolizing enzymes.
A systematic approach was used in developing the
PBPK models, starting by screening and extracting drug-
specific input parameters and clinical pharmacokinetic data
from the published literature, followed by the incorporation
of these data into the software and the selection of the
underlying physiological models and final model pa-
rameters, and ending with the final evaluation of model
predictions of drug disposition and absorption. The model-
building was done in a stepwise strategy similar to that
reported previously [20]. In this strategy, intravenous drug
application in healthy adult subjects is first simulated to
avoid the complexities of the oral absorption process so
that a wide range of drug-dependent parameters that govern
the drug disposition, including clearance inputs and the
percentage CYP enzyme contributions, are chosen or op-
timized. For oral application, parameters from the previous
step are kept, and additional parameters that control and
influence drug absorption, such as intestinal permeability,
are also included. In order to do so, one third (n = 3: one
intravenous and two oral) of the collected observed phar-
macokinetic data in adults were used to optimize the model
parameterization, two thirds (n = 6) were used later for a
subsequent model verification, and all data were used in the
final model evaluation. Changes of hepatic and renal blood
flows observed in CHF were then incorporated into this
adult model to predict carvedilol pharmacokinetics in CHF
patients. At the end, the final adult CHF model was then
scaled down to children, using the paediatric module of
Simcyp. In the adult and paediatric CHF populations,
predictions were made in duplicate, using both models,
i.e. with and without incorporation of the reduced organ
blood flows. The workflow for the development of the
PBPK models is shown in Fig. 1.
2.2 Model Structure and Parameterization
A comprehensive literature search was performed to ex-
tract necessary in vivo and in vitro ADME data to com-
plete the parameterization of the models. These data
include, for example, the drug-specific physicochemical
properties, drug clearance information and measures of
drug intestinal permeability. The final set of model input
parameters is summarized in Table 1. The two developed
models were similar in terms of all of the input parameters,
except for the method used for assigning clearance. A
detailed description of the various model components with
their parameterization is given below.
2.2.1 Absorption
The advanced dissolution, absorption and metabolism
(ADAM) model with the default values of fasting gastric
emptying time (mean 0.4 h with a coefficient of variation
[CV] of 38 %) and small intestinal transit time (mean
3.33 h with Weibull distribution, a = 2.92 and b = 4.04)
was used to predict drug absorption [21]. The predicted
human jejunum permeability (Peff,man) of carvedilol was
1.94 9 10-4 cm/s, which was obtained using in vitro Ca-
co-2 permeability (Papp) data calibrated with reference
values for propranolol and metoprolol [22]. In addition, the
predicted absorbed fraction of carvedilol was 0.896, which
is consistent with carvedilol being a highly permeable drug
belonging to Biopharmaceutics Classification System
(BCS) class II.
The Peff,man value was increased from 1.94 9 10
-4 to
7.4 9 10-4 cm/s in all simulations of adult and paediatric
subjects whenever carvedilol was administered as an oral
suspension, because of the observed increase in carvedilol
bioavailability. This optimization was achieved by com-
parison of the predicted pharmacokinetic parameters in
healthy adults with the observed data, after administration
of a 50 mg oral capsule and suspension [18]. Although fast
gastric emptying of liquid dosage formulations has already
been reported and can, theoretically, be a parameter to
adjust [23], it was not possible to account for the previously
mentioned increase in drug absorption by only reducing the
gastric emptying time.
With regard to active transport, there are some reports
suggesting a possible role of P-glycoprotein (P-gp) in
carvedilol disposition [17, 24]. However, the International
Transporter Consortium (ITC) has stated in its guidelines
and established decision trees that, when the net flux ratio
of a drug in a bidirectional transport assay, such as Caco-2,
is less than 2, then it is a poor or non-P-gp substrate [25],
which was the case with carvedilol (its net flux ratio is 1.3
[22]). This suggests that carvedilol is a poor substrate for
P-gp, which is in harmony with reports stating that
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carvedilol is a strong P-gp inhibitor but not a good sub-
strate [26]. In light of the aforementioned information, no
P-gp-specific data were incorporated into the developed
PBPK models.
2.2.2 Distribution
The full PBPK model for the prediction of drug distribution
was used in both developed models. The drug volume of
Fig. 1 Workflow for the development of adult and paediatric
physiologically based pharmacokinetic (PBPK) carvedilol heart
failure models. ADAM advanced dissolution, absorption and metabo-
lism, ADME absorption, distribution, metabolism and elimination,
AUClast area under the systemic drug concentration–time curve from
time zero to the time of the last measured concentration,
CI confidence interval, CL clearance, Cmax maximum concentration,
CYP cytochrome P450, fuP fraction of unbound drug in plasma,
HIM human intestinal microsomes, HLM human liver microsomes,
iv intravenous, LogPo:w octonal–water partition coefficient, Peff,-
man human jejunum permeability, PK pharmacokinetic, pKa acid
dissociation constant
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distribution at steady state (Vss) values and the specific
tissue-to-plasma partition coefficient (Kp) values were
calculated by the Paulin and Theil method with the
Berezhkovskiy correction [27]. As a result, the predicted
Vss value of 1.69 L/kg by this method was comparable to
the reported value of 1.62 L/kg1 in the literature [18].
2.2.3 Elimination
The human liver and human intestinal microsome CLint
values were used for the prediction of drug clearance in
model 1 [28, 29]. Model 2 used CYP enzyme CLint
values calculated by the retrograde model for enzyme
kinetics in Simcyp. The retrograde model is one of the
models incorporated in Simcyp that allows the calcula-
tion of CLint values of the relevant metabolizing enzymes
from in vivo measured clearance. A detailed description
of this model has already been published elsewhere [30,
31]. In brief, the retrograde model utilizes an in vivo
measure of the adult intravenous or oral clearance with
known fractions of hepatic clearance (CLH), renal clear-
ance (CLR) or any additional clearance, the unbound drug
fraction in plasma (fup), the blood-to-plasma ratio of the
drug concentrations, and QH to calculate total hepatic
CLint as given in the following equation of the well-stir-
red liver model (Eq. 1):
CLint ¼ QH  CLH
fuB  ðQH  CLHÞ ð1Þ
Table 1 Main drug-dependent parameters and characteristics of the presented physiologically based pharmacokinetic (PBPK) models
Parameter Model 1 Model 2 Reference value References
Molecular weight (g/mol) 406.47 406.47 406.47 PubChem
LogPo:w 4.19 4.19 4.19 PubChem
pKa 7.97 7.97 7.97 [55]
Absorption
Model ADAM
Peff,man (cm/s) in tablets and capsules
a 1.94 9 10-4 1.94 9 10-4 1.94 9 10-4 [22]
Peff,man (cm/s) in oral suspension
b 7.4 9 10-4 7.4 9 10-4 – –
Distribution
Model Full PBPK
Prediction methodc Paulin and Theil method
B:P ratio 0.69 0.69 0.69 [56]
fuP 0.0054 0.0054 0.0054 [56]
Elimination
CLiv (L/h) – 38 35.34
d [18]
HLM CLint (lL/min/mg protein) 246 – 246 [28]
Fraction unbound in microsomal incubation 0.04 – 0.04 [28]
HIM CLint (lL/min/mg protein) 11.4 – 11.4 [29]
CYP2D6 CLint (lL/min/mg/pmol of isoform)
e – 339.7 – –
CYP1A2 CLint (lL/min/mg/pmol of isoform)
e – 8.71 – –
CYP2C9 CLint (lL/min/mg/pmol of isoform)
e – 3.1 – –
CYP2E1 CLint (lL/min/mg/pmol of isoform)
e – 3.71 – –
Additional HLM clearance (lL/min/mg protein)e – 906.7 – –
CLR (L/h) 0.25 0.25 0.25 [34]
ADAM advanced dissolution, absorption and metabolism, B:P blood-to-plasma, CLint intrinsic clearance, CLiv intravenous clearance, CLR renal
clearance, CYP cytochrome P450, fuP fraction of unbound drug in plasma, HIM human intestinal microsomes, HLM human liver microsomes, Kp
tissue-to-plasma partition coefficient, LogPo:w octonal–water partition coefficient, Papp in vitro permeability, Peff,man human jejunum perme-
ability, pKa acid dissociation constant, Vss drug volume of distribution at steady state
a Peff,man calculated from the Papp value of a Caco-2 assay by calibration with metoprolol and propranolol, using Simcyp

b Optimized Peff,man
c Paulin and Theil method with the Berezhkovskiy correction, as the prediction method for Vss and Kp (predicted Vss 1.69 L/kg)
d CLiv range 22.5–50.8 L/h
e Values calculated by using the retrograde model in Simcyp
1 Vss was calculated by using non-compartmental analysis in Phoenix
WinNonLin software (Pharsight Corporation, CA, USA).
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In a second step, this hepatic CLint value is divided
between the involved hepatic elimination pathways
(i.e. the different CYP enzymes), using input information
about the percentage contribution of these metabolizing
enzymes in drug clearance.
The contributions of the CYP enzymes that are involved
in carvedilol metabolism were guided by the available
evidence in the literature. It has been reported that
CYP2D6 is the major contributing CYP enzyme, while
CYP1A2, CYP2C9, CYP2E1 and CYP3A4 are involved
with a minor role [17, 32, 33]. In the literature, there is no
clear information about the relative contributions of the
CYP enzymes to the total carvedilol clearance, except for
that of CYP2D6 (50–62 % [17, 33]). From the remaining
CYP enzymes believed to be involved in the metabolic
pathways of carvedilol, CYP1A2, CYP2C9 and CYP2E1
were reported to be of further importance [32]. In light of
the aforementioned information and the fact that the rela-
tive amount of carvedilol glucuronidation is around 22 %
[14], 80 % of total carvedilol clearance was assigned to the
following CYP enzymes—60 % CYP2D6, 10 % CYP1A2,
5 % CYP2C9 and 5 % CYP2E1—and the remaining 20 %
was assigned to glucuronidation as additional clearance.
A CLR value of 0.25 L/h was used in both models 1 and 2
[34].
Three different uridine diphosphate glucuronosyltrans-
ferase (UGT) enzymes are believed to be involved in the
metabolism of carvedilol: UGT1A1, UGT2B4 and
UGT2B7. In the literature, there is no clear information
about their individual relative contributions to the
metabolic clearance of carvedilol; therefore, the collective
impact of these UGT enzymes was reflected in an assigned
additional clearance, which constituted about 20 % of the
total carvedilol clearance. This is in a good agreement with
the reported values of 20–23 % in healthy adults [14].
In model 1, a CV of 30 % was assigned to HIM and
HLM CLint. In model 2, a CV of 30 % was assigned to the
additional clearance, whereas for the CYP enzyme CLint
values obtained by the retrograde model, the observed
variability was due to variations in the physiological and
anatomical variables, such as liver weight, microsomal
proteins per gram of liver, abundance of each specific CYP
enzyme, cardiac output and QH.
CLH was predicted from the well-stirred liver model
[35], using Eq. 2:
CLH ¼ QH  fuB  CLuH;int
QH þ fuB  CLuH;int ð2Þ
The QH changes occurring in CHF were incorporated into
the model for prediction of the disposition of carvedilol in
patients with CHF.
The oral bioavailability (F) was predicted by using
Eq. 3:
F ¼ Fa  Fg  Fh ð3Þ
where Fa is the fraction of the drug absorbed, Fg is the
fraction escaping metabolism in the gastrointestinal tract
and Fh is the fraction escaping hepatic metabolism.
2.3 Model Scaling to Children
Only when the adult CHF models were shown to predict
carvedilol pharmacokinetics adequately were they scaled to
the children by using the paediatric module of Simcyp.
This module of the program incorporates a wide variety of
age-specific physiological and anatomical parameters,
which facilitates the paediatric scaling of drug clearance on
a physiological basis. Because of the use of an oral sus-
pension of carvedilol in both paediatric clinical trials [15],
an optimized value of Peff,man was used in all paediatric
predictions, as in the adults who were administered the oral
suspension of carvedilol. The paediatric module of the
program also accounts for the age-related changes occur-
ring in the total body composition, when predicting dis-
tribution of drugs [36]. The key determinants for predicting
drug clearance in the paediatric module are the age-specific
changes occurring in plasma protein binding, blood vol-
ume, organ blood flows, organ sizes and ontogeny, and the
abundance of hepatic CYP enzymes [36]. In model 2, the
ontogeny profiles of the CYP enzymes were incorporated
by default within the program, but in model 1, in order to
create an ontogeny profile similar to that of model 2, a
customized ontogeny profile was created by addition of the
fractional contributions of the CYP enzymes with their
respective ontogenies [32, 33, 37]. All of the paediatric
patients were diagnosed with CHF, and the reductions in
hepatic and renal blood flows were incorporated into the
paediatric models by categorization of the patients into
different CHF categories, according to their modified Ross
scores [38].
2.4 Changes in Blood Flow to Eliminating Organs
in Heart Failure
The liver and kidney are the main organs of drug
elimination from the human body; therefore, changes in the
blood flows to these organs are of pharmacokinetic im-
portance. In adult heart failure patients, the reduction in QH
is known to increase with increased severity of the disease
[9]. In brief, these organ blood flow reductions occurring in
adult heart failure patients were quantified after measure-
ment of the hepatic and renal plasma flows in healthy and
heart failure patients by administration of doses of intra-
venous indocyanine green and intravenous p-aminohippu-
rate and measurement of their respective clearances [9].
The quantified reductions were 23.5, 46.2 and 53.7 % of
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normal QH in mild, moderate and severe CHF patients,
respectively [9]. Moreover, the reduction in renal blood
flow was also shown to be greater with increased severity
of CHF; however, this reduction is not absolutely linear
when we move from moderate to severe CHF, as it has
been reported to be around 22.2, 45 and 37.1 % of normal
blood flow in mild, moderate and severe CHF patients,
respectively [9].
In adult patients, the New York Heart Association
(NYHA) functional classification system provides a simple
way of classifying the severity of CHF [39], where, for
example, NYHA class II reflects mild CHF and class III
reflects moderate CHF, whereas class IV stands for severe
CHF [39]. As a result, the reported reductions in blood
flows to the liver and the kidney could be directly corre-
lated in adults with the NYHA classification. In order to
predict drug exposure in CHF patients, using a PBPK
model, these reductions in organ blood flows were assigned
to the simulated virtual populations within Simcyp by
reduction of the percentage blood flows to the liver and
kidney, respectively. When the drug exposure in a
population comprising NYHA class III (moderate CHF)
and class IV (severe CHF) patients had to be predicted, the
mean organ blood flow reductions in moderate and severe
CHF from the reported values were used [9], i.e. reductions
of 49.9 and 41 % of the normal hepatic and renal blood
flows, respectively.
In paediatric CHF patients, because of the difficulty in
assessing physical activity, the NYHA classification is not
used to assess the severity of the CHF; instead, the Ross
score is the system commonly used in children [40]. Ac-
cording to the Ross score, a score of 0–2 categorizes the
patient as asymptomatic, 3–6 as having mild CHF, 7–9 as
having moderate CHF and 10–12 as having severe CHF
[38, 40]. As there were no experimental data available to
quantify the reduction of hepatic and renal blood flows in
paediatric CHF patients and to correlate them with the
paediatric CHF classification system, the proposed changes
in the paediatric CHF model were adopted from the pre-
viously mentioned adult values [9]. The relative reductions
in the organ blood flows and their associations with the
severity of CHF according to the NYHA classification and
the Ross score are shown in Fig. 2.
2.5 Pharmacokinetic/Clinical Data
2.5.1 In Adults
The Medline database was screened for pharmacokinetic
studies of carvedilol in healthy adults and CHF patients
with known age, sex, height or weight data, clear dosing
information and reported systemic drug concentration–time
profiles. As a result, pharmacokinetic data from four
different clinical studies in healthy subjects (3 studies to-
talling 41 subjects) and CHF patients (one study of ten
patients with NYHA class III and ten patients with class IV
CHF) were used in the adult model development and
evaluation [13, 15–17]. These studies provided a total of
nine data sets (five data sets in healthy subjects and four
data sets in CHF patients) (Table 2). Each experimental
data set represented a mean or median observed concen-
tration–time profile in an average of 18 subjects who re-
ceived either intravenous or oral doses of carvedilol. The
average number of observed concentrations in these data
sets was 13 (the total number was 122). These data sets
were either provided by the author [15] or scanned from the
publications’ figures [13, 16, 17], using the digitizer tool in
the data analysis and graphing software OriginPro ver-
sion 9.0 (OriginLab, Northampton, MA, USA). In addition,
one study that reported only the pharmacokinetic pa-
rameters, but not the concentration–time profiles, after
administration of oral suspension in healthy subjects was
additionally used in the comparison of the observed and
predicted values of the chosen pharmacokinetic parameters
[18].
2.5.2 In Children
Two clinical data sets, including 32 paediatric CHF pa-
tients of different age groups with known age, sex, height
and weight data, dosing information, Ross scores and
measured plasma profiles were used (Table 3) [15]. The
ages of the patients ranged from 43 days to 19.3 years
(average 7.3 years), and they received either a 0.09 mg/kg
single dose or 0.35 mg/kg steady-state doses of oral car-
vedilol for the treatment of CHF. The average number of
measured concentrations in each patient was 12 (the total
numbers were 197 and 202 for single-dose and steady-state
sampling). In our paper, no explicit paediatric age groups
were used, as the total number of the included paediatric
patients was relatively small, with an unequal distribution
between the different paediatric age subcategories. When-
ever the term ‘‘children’’ is used, this refers to the entire
paediatric age group ranging from birth to 18 years. The
19.3-year-old patient has been shown separately in the
results, as this patient was out of the paediatric age range
according to the guidelines set by the World Health Or-
ganization (WHO).
2.6 Model Evaluation
The simulations were performed by creation of a virtual
population of 100 subjects for each clinical data set with
the same age range, proportion of females, fluid intake and
fasting/fed states as those in the reference clinical studies.
The predictions performed with greater numbers of virtual
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individuals (500 or 1000) produced no significant differ-
ences in comparison with the previous results (100 virtual
individuals); therefore, as reported in other model-based
PBPK studies [41–43], a virtual population of 100 indi-
viduals was always used for comparison with the observed
profiles. Patient/population-specific genotype data were
available from two clinical studies [15, 17], and the
simulated virtual populations with use of model 2 had the
same frequencies of genotypes as those in the reported
clinical studies.
Fig. 2 Changes in hepatic and
renal blood flows in patients
with heart failure, as
incorporated into the developed
physiologically based
pharmacokinetic heart failure
models of carvedilol. The
presented data are taken from
Leithe et al. [9]. NYHA New
York Heart Association class
Table 2 Characteristics of the adult data sets used for carvedilol mode development




Application Age (years) Proportion of
females
Body weight (kg) References
Mean Range Mean Range
1 Healthy 12 5 Intravenous infusiona,b – 21–29 0.25 – 59–92 [17]
2 Healthy 20 12.5 Intravenous infusiona – 19–45 0 – 60–92 [13]
3 Healthy 9 6.3c Oral 29.6d 24–37 0.66 69.8e 56–100 [15]
4 Healthy 20 25 Oral – 19–45 0 – 60–92 [13]
5 Healthy 20 50 Oral – 19–45 0 – 60–92 [13]
6 Healthy 20 50 Oralf – 19–45 0 – 60–92 [18]
7 Heart failureg,h 20 6.25 Oral 55i 39–64i 0 89.5i 60.8–113.1i [16]
8 Heart failureg,h 20 12.5 Oral 55i 39–64i 0 89.5i 60.8–113.1i [16]
9 Heart failureg,h 20 25 Oral 55i 39–64i 0 89.5i 60.8–113.1i [16]
10 Heart failureg,h 20 50 Oral 55i 39–64i 0 89.5i 60.8–113.1i [16]
NYHA New York Heart Association
a The intravenous infusion was given over 1 h
b The mean of the reported individual profiles was used for comparison
c Dose administered as 0.09 mg/kg but normalized to total dose by multiplication by the average weight of the participants in the clinical trial
d Median age 27 years, standard deviation 5.4, 25th and 75th percentiles 24.5 and 35 years
e Median weight 65 kg, standard deviation 15.04, 25th and 75th percentiles 58.05 and 80.25 kg
f Suspension
g The mean results reported in the study were further subdivided into NYHA class III and class IV subgroups
h The population included 10 patients with NYHA class III and 10 with class IV heart failure
i The presented values for age and weight are the reported values for the initial study population (n = 22)
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The evaluation of the developed PBPK models was
performed by visual predictive checks and a comparison of
the observed and predicted values of various pharmacoki-
netic parameters. In the visual predictive checks, the
complete observed systemic drug concentration–time pro-
file was overlaid on the predicted values so that a direct
visual comparison could be made.
For the comparison of pharmacokinetic parameters, a
non-compartmental analysis (NCA) was performed for
each observed profile and its corresponding predicted value
in each model (i.e. using the predicted values at the same
time points), using Phoenix WinNonLin version 6.3
software. The area under the systemic drug concentration–
time curve from time zero to the time of the last measured
concentration (AUClast) was calculated via the linear
trapezoidal rule. The maximum concentration in a profile
was defined as Cmax, and the clearance (CL for intravenous
application and CL/F for oral application) was calculated
by division of the given dose by the calculated AUClast.
Following the NCA, the observed/predicted ratio (ra-
tioObs/Pred) values for the pharmacokinetic parameters were
then calculated, and the final results were reported as mean
ratio(Obs/Pred) values with 95 % confidence intervals
(95 % CIs).
To the best of our knowledge, there are no clear
guidelines regarding the error range that should be used
during the evaluation of predictions obtained by PBPK
models. The range most commonly used by researchers in
this field is a 2-fold error range [3, 20, 44–47]. Others have
also used a wider (3-fold) range [48] or a stricter (1.5-fold)
range [49]. In our case, and because the models were used
to perform predictions in both adults and children, and
Table 3 Characteristics of the paediatric data used for model development
No. Age (years) Sex Body weight (kg) Single dose (mg/kg) Steady-state dose (mg/kg) Ross score/NYHA class
Patients categorized according to their Ross score
1 0.12 Female 3.1 0.09 0.35 Score 3
2 0.15 Male 3.9 0.09 0.35 Score 3
3a 0.25 Female 4.2 – 0.35 Score 4
4 0.5 Female 5.2 0.09 0.35 Score 8
5b 0.75 Male 8 0.09 – Score 3
6 1.25 Male 10.1 0.09 0.35 Score 3
7 1.5 Male 9.5 0.09 0.35 Score 10
8 3.5 Female 13.1 0.09 0.35 Score 3
9b 5.5 Male 20.2 0.09 – Score 3
10 7.5 Male 24.3 0.09 0.35 Score 5
11 8.25 Male 25.8 0.09 0.35 Score 7
12 10.75 Male 25.5 0.09 0.35 Score 4
13 11.6 Female 34.3 0.09 0.35 Score 4
14 11.8 Male 39 0.09 0.35 Score 2
15a 13.5 Male 52 – 0.35 Not available
Patients categorized according to their NYHA classification
16 17.5 Male 56 0.09 0.35 Class II
17 17.8 Male 61 0.09 0.35 Class III
18 19.3c Male 98.2 0.09 0.35 Class III
Mean 7.3 27.41 – – –
Standard deviation 6.76 25.65 – – –
Median 6.5 22.25 – – –
25th percentile 0.68 7.3 – – –
75th percentile 12.23 42.25 – – –
All of the children were diagnosed with heart failure and were participants in the same clinical trial [15]
NYHA New York Heart Association
a Measured concentrations available only at steady state
b Measured concentrations available only after a single dose
c Patient out of the paediatric age range according to guidelines set by the World Health Organization
PBPK Model for Carvedilol Exposure in Heart Failure 951
because of the high variability observed in the reported
pharmacokinetic parameters of carvedilol, a 2-fold error
range was used and was considered to be adequate.
Moreover, goodness-of-fit plots, population-predicted
versus population-observed plots, residuals versus popula-
tion-predicted plots and residuals versus time plots were
used for identifying systemic errors in the developed
models.
Depending upon the reported values of the pharma-
cokinetic parameters, the predicted mean or median values
of the pharmacokinetic parameters were used for compar-
ison and calculation of ratio(Obs/Pred) values.
3 Results
3.1 Healthy Adults
The observed and predicted systemic drug concentration–
time profiles after the administration of intravenous and
oral carvedilol in healthy adults are shown in Fig. 3, and
the residual plots are shown in Fig. 4. The results from
both models were in good agreement with the observed
data irrespective of the administered doses of 5–12.5 mg of
intravenous carvedilol and 6.3–50 mg of oral carvedilol.
However, model 2 was superior to model 1 in terms of
capturing the absorption phase, as model 1 tended to
slightly overpredict early drug concentrations. This was
further confirmed during comparison of the pharmacoki-
netic parameters, as the resultant mean AUClast ratio(Obs/
Pred) values after intravenous application were 1.12
(95 % CI 1.01–1.22) and 0.97 (95 % CI 0.78–1.16), using
models 1 and 2, respectively, and after oral application they
were 0.80 (95 % CI 0.51–1.11) and 0.94 (95 % CI
0.65–1.23), using models 1 and 2, respectively. In addition,
the calculated mean ratio(Obs/Pred) values for AUClast, Cmax,
CL and CL/F were within the defined 2-fold error range
(Fig. 5a–c).
3.2 Adult Heart Failure Patients
The observed and predicted systemic drug concentration–
time profiles after administration of steady-state oral doses
of carvedilol (6.25–50 mg) in NYHA class III and class IV
CHF patients are shown in Fig. 3. The visual predictive
checks show a substantial improvement in the predictions
after incorporation of reduced organ blood flows in the
models. The mean AUClast ratio(Obs/Pred) values without
adjustment of the organ blood flows were outside the 2-fold
error range in both models, i.e. 2.33 (95 % CI 2.02–2.63)
in model 1 and 2.65 (95 % CI 2.29–3.01) in model 2. After
incorporation of the proposed organ blood flow changes,
these ratios improved to 0.79 (95 % CI 0.69–0.90) and
1.03 (95 % CI 0.89–1.16), respectively. The complete
comparison of the calculated pharmacokinetic parameters
with and without adjustment of organ blood flows is shown
in Fig. 5a–c. Similar results were seen after further
categorization of the CHF patients into NYHA class III and
class IV subgroups. The developed models were capable of
predicting carvedilol exposure in NYHA class III and
class IV patients, as can be seen by the mean ratio(Obs/Pred)
values and their 95 % CIs (Fig. 5d–f). Despite the fact that
the predicted concentrations in both models were within a
2-fold error range (Fig. 4), it can be noticed that model 1
tended to overpredict drug concentrations in the absorption
phase at all dosage levels, whereas model 2 predictions
were in closer agreement with the observed data.
Similarly, the mean CL/F ratio(Obs/Pred) values without
reduction of organ blood flows were outside the 2-fold
error range, i.e. 0.34 (95 % CI 0.31–0.37), in both models,
and were significantly improved to 1.0 (95 % CI
0.92–1.08) and 0.95 (95 % CI 0.88–1.03) in models 1 and
2, respectively. The predicted bioavailability (F) and Fh
decreased with a decrease in QH (increase in severity of
CHF). The predicted effect of the decreased QH on car-
vedilol CL/F and bioavailability in the different stages of
heart failure can be seen in Fig. S1 in the Electronic
Supplementary Material.
3.3 Paediatric Heart Failure Patients
Carvedilol exposure after single and steady-state doses of
0.09 and 0.35 mg/kg, respectively, was predicted using
both models in the entire paediatric age range (see Fig. S2
in the Electronic Supplementary Material). It can be seen
that both models were able to describe the individual
plasma concentration–time points; however, model 2 was
again better when compared with model 1, with a greater
number of observed plasma concentration–time points
within the maximum and minimum prediction range
(*93 % for model 2 versus *86 % for model 1).
cFig. 3 Comparison of observed and predicted systemic carvedilol
concentration–time profiles in healthy subjects and heart failure
patients after intravenous (iv) or oral drug dosing. Healthy adults, iv
application: a, b 5 mg [17], c, d 12.5 mg [13]. Healthy adults, oral
application: e, f 0.09 mg/kg [15], g, h 25 mg [13], i, j 50 mg [13].
Heart failure patients, oral application: k, l 6.25 mg [16], m,
n 12.5 mg, o, p 25 mg, q, r 50 mg. The observed data are shown
as mean values (a, b, k–r) or as median values (c–j) of the study
population. Standard deviations were available only for e, f. Prediction
results are shown for model 1 or model 2 as median or mean values
(solid lines), 5th and 95th percentiles (dotted lines) and minimum/-
maximum values (dashed lines). Prediction results in heart failure
patients (k–r) are for the modified model with reduced organ blood
flow, whereas dashed grey lines indicate mean model predictions
without incorporation of organ blood flow changes
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Fig. 4 Goodness-of-fit plots for model predictions in the adult
population, presented as a, d, g, j predicted versus observed
concentration plots; b, e, h, k residuals versus predicted concentration
plots; and c, f, i, l residuals versus time plots. a–c Intravenous (iv)
dosing in healthy adults. d–f Oral dosing in healthy adults. g–i Oral
dosing in heart failure patients without renal and hepatic blood flow
reductions. j–l Oral dosing in heart failure patients with renal and
hepatic blood flow reductions. Solid lines indicate lines of identity,
dashed lines indicate 2-fold error ranges, open squares indicate
results from model 1 and filled circles indicate results from model 2
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The individual predictions made by model 2 after ad-
ministration of a single oral dose of carvedilol 0.09 mg/kg
to 15 paediatric patients and one young adult are shown for
a visual predictive check in Fig. 6, with and without re-
duction of organ blood flows. In addition, the residual plots
are given in Fig. 7. In general, the model was able to
Fig. 5 Comparison of observed and predicted values of the area
under the systemic drug concentration–time curve from time zero to
the time of the last measured concentration (AUClast), the maximum
concentration (Cmax) and calculated oral drug clearance (CL/F) in
healthy adult and heart failure populations. Results are presented as
individual and mean observed/predicted ratio [ratio(Obs/Pred)] values
with 95 % confidence intervals (95 % CIs), using model 1 and
model 2. a–c Filled circles indicate healthy adults, filled squares
indicate heart failure patients without renal and hepatic blood flow
reductions, and inverted filled triangles indicate heart failure patients
with renal and hepatic blood flow reductions. d–f Filled circles and
filled squares indicate heart failure patients in New York Heart
Association (NYHA) class III and class IV, respectively, without
renal and hepatic blood flow reductions; inverted filled triangles and
diamonds indicate heart failure patients in NYHA class III and
class IV, respectively, with renal and hepatic blood flow reductions.
The grey shaded areas indicate 2-fold error ranges. iv intravenous,
n number of data sets
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predict carvedilol concentrations accurately in all patients
above 1 year of age (12 out of 16). For the one patient with
symptomatic CHF (a Ross score of 0–2), no changes in
blood flows were incorporated; therefore, there was no
change to be seen in the visual predictive check. For the ten
paediatric patients with mild CHF, nine were with Ross
scores of 3–6, the incorporation of blood flow reductions
did not improve the predictions in these patients but im-
provement was seen in one patient classified with NYHA
class II (see also the pharmacokinetic comparison). Con-
cerning the four patients with moderate CHF, the model
predictions were better without organ blood flow
reductions in those patients classified with Ross scores
(n = 2, with scores of 7–9), whereas in the remaining two
who were classified as being in NYHA class III, the pre-
diction was clearly improved in one patient (19.3-year-old
patient) but no improvement was seen in other NYHA III
patient (17.8-year-old patient) with reductions in organ
blood flows.
The mean AUClast ratio(Obs/Pred) values and 95 % CIs
after administration of a single dose (0.09 mg/kg) of car-
vedilol were 0.98 (95 % CI 0.68–1.28) and 1.0 (95 % CI
0.7–1.30) without incorporation of reduced organ blood
flows. There was no improvement seen in the prediction
capability of both models with reduction of organ blood
flows, after administration of single and steady-state doses
of carvedilol, as the calculated ratio(Obs/Pred) values for
AUClast, Cmax and CL/F were further away from unity
(Fig. 8). The previous finding that predictions in adult CHF
patients, classified with NYHA system improved after re-
duction of organ blood flows was also seen here in two
patients (17.5 years NYHA II and 19.3 years NYHA III).
bFig. 6 Individual predictions made by model 2 after administration
of a single oral test dose of carvedilol 0.09 mg/kg with adjustment of
organ blood flows (shown by open circles) and without adjustment of
organ blood flows (shown by filled circles). Solid lines indicate
median predictions, dashed lines indicate minimum and maximum
predictions, dotted lines indicate 5th and 95th percentiles, and filled
and open circles indicate observed data [15]. NYHA New York Heart
Association
Fig. 7 Goodness-of-fit plots for
model 2 predictions in the
paediatric population, presented
as a, d median predicted versus
individual observed
concentrations plots; b,
e residuals versus median
predicted concentrations plots;
and c, f residuals versus time
plots. a–c Results without renal
and hepatic blood flow
reductions, shown by filled
circles. d–f Results with renal
and hepatic blood flow
reductions, shown by open
circles. Solid lines indicate lines
of identity, and dashed lines
indicate 2-fold error ranges
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The observed carvedilol CL/F increased with age after
administration of the single dose of 0.09 mg/kg, starting
from 9.20 L/h in a patient aged 0.12 years and reaching up
to 110 L/h in a patient aged 19.3 years. When the CL/
F was normalized for weight, a decrease was seen with
increasing age, as it decreased from 2.94 L/h/kg at the age
of 0.12 years to 1.12 L/h/kg until the age of 19.3 years,
which is a reflection of the incorporated knowledge of
enzyme ontogeny in the modelling software. A similar
trend was seen after administration of steady-state target
doses of carvedilol. The developed models were capable of
capturing the age-related changes in carvedilol CL/F after
single and steady-state administration (see Fig. S3 in the
Electronic Supplementary Material).
4 Discussion
In this study, reduced hepatic and renal blood flows were
incorporated into whole-body PBPK models to predict
carvedilol exposure in CHF patients. Both of the developed
models were able to describe carvedilol pharmacokinetics
in adults and paediatric subjects over 1 year of age, but
model 2 was shown to be superior to model 1 in its pre-
dictive performance. The incorporation of the reduced
hepatic and renal blood flows into the developed CHF
models resulted in a significant improvement in predictions
of drug exposure in adult patients. Conversely, the incor-
porated blood flow reductions did not result in any im-
provements in the paediatric CHF patients, except in those
Fig. 8 Comparison of observed and predicted values of the area
under the systemic drug concentration–time curve from time zero to
the time of the last measured concentration (AUClast), the maximum
concentration (Cmax) and oral drug clearance (CL/F) in paediatric
heart failure patients after administration of a single dose of 0.09 mg/
kg. The results are presented as individual and mean observed/
predicted ratio [ratio(Obs/Pred)] values with 95 % confidence intervals
(CIs), without blood flow reductions (shown by filled circles) and
with blood flow reductions (shown by filled squares). The grey
shaded areas indicate 2-fold error ranges. a–c Results from both
models, stratified by age. d–i Results from model 2, stratified by the
severity of the disease. NYHA New York Heart Association class
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patients who were categorized according to NYHA clas-
sification of heart failure (NYHA II and NYHA III) as in
adults.
Following the implemented strategy of model develop-
ment, the presented models were first parameterized and
evaluated in healthy adults. The results showed accurate
prediction of carvedilol exposure over a wide range of
administered intravenous and oral doses (Figs. 3, 4, 5),
which supported the ability of the models to account for the
various processes governing drug absorption and disposi-
tion. The predicted bioavailability in healthy volunteers
was in the range of 15–27 % according to both models,
which was quite close to the reported values of 22–24 %
[18]. Furthermore, the mean AUClast ratio(Obs/Pred) values in
healthy adults were within the 2-fold error range, i.e. after
intravenous application: 1.12 (95 % CI 1.01–1.22) and
0.97 (95 % CI 0.78–1.16), using models 1 and 2, respec-
tively; and after oral application: 0.80 (95 % CI 0.51–1.11)
and 0.94 (95 % CI 0.65–1.23), respectively.
In CHF, hepatic and renal blood flows decrease with in-
creasing severity of the disease [9]. Incorporation of these
reductions improved the model predictions significantly—
for example, the mean AUClast ratio(Obs/Pred) values changed
from 2.33 (95 % CI 2.02–2.63) to 0.79 (95 % CI 0.69–0.90)
and from 2.65 (95 % CI 2.29–3.01) to 1.03 (95 % CI
0.89–1.16), using models 1 and 2, respectively. The exten-
sive first-pass effect and the high hepatic extraction ratio of
carvedilol [11, 13, 18] imply that changes in QH, as seen in
CHF, will influence its first-pass and systemic hepatic
metabolism—and thus its bioavailability and total exposure.
The reduced QH will lead to an increase in first-pass meta-
bolism, with a subsequent decrease in drug bioavailability
(because of higher hepatic extraction during the first pass)
and a decrease in the systemic clearance of the drug. The
reduction in carvedilol bioavailability and CL/F with the
increased severity of CHF was clearly seen in the predictions
(see Fig. S1 in the Electronic Supplementary Material). On
the other hand, the CLR of carvedilol is only about 1–2 %
[13, 34] of its total clearance; therefore, the change in the
latter can clearly be attributed to the decrease in CLH. The
ratio(Obs/Pred) values and 95 % CIs for the pharmacokinetic
parameters after further subdivision of the adult CHF pa-
tients into NYHA class III and class IV categories supported
our hypothesis that the incorporated reduced hepatic and
renal blood flows in the developed models are associated
with the NYHA classification of CHF (Fig. 5).
The previously presented and evaluated models in adults
formed the basis for extrapolation of carvedilol pharma-
cokinetics to children on a physiological basis, using the
paediatric module in Simcyp. The developed paediatric
models, which incorporate a wide range of age-specific in-
formation, were capable of reflecting carvedilol exposure
after single and steady-state doses in the paediatric age range
(see Fig. S2 in the Electronic Supplementary Material).
However, it was noticed that the models tended to generally
overpredict the drug concentrations in those patients under
1 year of age, with or without incorporation of blood flow
reductions. An overprediction of drug concentrations in this
age group was previously reported when child-specific
PBPK models were used to predict the pharmacokinetics of
drugs when they were given orally [20], which was mostly
attributed to age-specific information gaps in the pa-
rameterization of the integrated absorption models. Second,
in contrast to the adult patients, the improvement in the
model predictions with incorporation of blood flow changes
was limited to a few cases, as is discussed below.
Ten out of the 14 paediatric CHF patients who were
included in the clinical trial were diagnosed with mild
CHF—nine patients according to the modified Ross scoring
system and one patient according to the NYHA classifi-
cation. For patients categorized with Ross score, no sub-
stantial improvement in predictions were seen, on the other
hand prediction was improved in one patient who was
staged NYHA II when reduced organ blood flows were
incorporated (Fig. 6). These findings could suggest that the
pharmacokinetics of carvedilol in young children may not
be affected in mild CHF as they are in moderate or severe
CHF. On the other hand, no improvement was seen when
the model was modified for blood flow changes in the only
patient with severe CHF, as indicated by a Ross score of
10, whereas clear improvement was only seen in 19.3 years
patient staged as NYHA class III and the 17.8 years patient
staged as NYHA class III was better described without
organ blood flow reductions. As a result, an assumption
that the Ross scoring system is poorly correlated with the
reductions in organ blood flows in comparison with the
NYHA classification for grading CHF cannot be com-
pletely excluded. In the modified Ross score system, dif-
ferent subjects with different symptoms may end up having
the same score and CHF category. Among the six cate-
gories used for classification of paediatric patients ac-
cording to the modified Ross scoring system, three are
related to breathing, which may result in undermining of
the other symptoms associated with CHF in paediatric
patients [50]. In addition, the aetiology and the patho-
physiology of CHF are different in adults when compared
with children, especially in the first few years after birth.
Children have higher heart rates [51] than adults [52],
which decease with age after birth and become comparable
to those of adults at the age of 18 years [51]; therefore,
children may have a greater capacity to compensate for a
decrease in cardiac output. Our paediatric disease model is
based on the adult heart failure model with its incorporated
reductions in organ blood flows, because in paediatrics, we
are not aware of any study that has quantified hepatic and
renal blood flow reductions with respect to different stages
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of heart failure in paediatric patients. Therefore, these adult
quantifications may not be completely true for children.
Finally, children also have a higher percentage of liver
weight to total body weight when compared with adults
[53], which may lead to a higher drug clearance capacity
(by rapidly maturating and abundant metabolizing en-
zymes), and decreased QH may not have the same impact
on drug clearance as it does in adults.
The observed weight-normalized carvedilol CL/F de-
creased in paediatric patients with increasing age (from
43 days to 17.8 years). This was due to the fact that infants
have a liver weight of around 4 % of their total body
weight, which decreases to about 2 % in adults [53].
Moreover, CYP2D6 is the major enzyme involved in car-
vedilol metabolism (*60 %), and it achieves more than
50 % of its adult activity within the first month of life [37].
Another enzyme that plays a minor role in carvedilol
metabolism is CYP2C9, which also has a fast ontogeny;
therefore, it was previously reported that significantly
higher weight-normalized doses, as compared with those
used in adults, are required in young children receiving
drugs that are primarily metabolized by this enzyme [54].
Furthermore, the decrease in carvedilol CL/F can also be
attributed to decreases in organ blood flows, as improve-
ment in predictions were seen with incorporation of re-
duced organ blood flows in patients within the adolescent
age group (Fig. 6). The developed paediatric models were
capable of capturing the age-specific changes in carvedilol
clearance, as the mean CL/F ratio(Obs/Pred) values after
administration of a single dose of carvedilol, without in-
corporation of reduced organ blood flows, were 1.44
(95 % CI 0.77–2.11) and 1.43 (95 % CI 0.72–2.14) with
use of models 1 and 2, respectively (Fig. 8).
Despite the fact that the already incorporated ontogeny
profiles for each of the individual CYP enzymes gave
model 2 a clear advantage over model 1 through its ability
to incorporate enzyme-specific genotype data, the predicted
results obtained by both models were very similar. One
reason could be that the customized ontogeny profile that
was assigned in model 1 is based on the ontogeny data of
each of the individual enzymes used in model 2. A second
reason is that the additional superiority of model 2 could
have been clearer if population-specific enzyme genotype
data had been included for all of the clinical studies that
were used. In our study, this was done in the simulations of
just two clinical studies [15, 17].
5 Limitations
Some of the carvedilol concentration–time profiles ob-
served in adults were scanned from the publications’ fig-
ures rather than being obtained from their sources.
However, the difference seen between the reported phar-
macokinetic parameters in the original papers and those
calculated by us using the scanned profiles was negligible
and therefore of no significance to the model evaluation
results. In addition, the adult CHF model was evaluated
only with NYHA class III and class IV patients, but this
was because of the availability of only one pharmacoki-
netic study of carvedilol in CHF patients.
The absorption (ADAM) model used for paediatric
simulations was not completely parameterized with age-
specific information for all of the anatomical and physio-
logical factors that may influence drug absorption. For
example, the model contains information on age-related
changes in intestinal length, diameter, blood flows and
intestinal CYP enzymes but no information on changes in
gastric and intestinal pH, bile secretion, transporters and
gut fluid dynamics. This reflects the fact that paediatric
drug absorption in PBPK modelling software is an area of
ongoing research; therefore, the presented paediatric results
must be judged in this context. The fluid intake with the
dose was not modified according to the age of the paedi-
atric subjects; however, no relevant impact on the results
from the four infants under 1 year of age was seen. The
assigned Peff,man value was not changed with age, and so a
similar passive diffusion of the substance was assumed in
adults and children.
The role of the three different UGT enzymes involved in
carvedilol metabolism was assigned collectively as an ad-
ditional clearance. Since each of these pooled UGT en-
zymes possesses a different ontogeny profile, and we have
no clear information about their individual contributions,
no specific ontogeny was assigned to this collective value.
This could be a limitation in model 2 and an aspect for
improvement of the model in the future.
Finally, in the presented models, we assumed that organ
blood flow reductions in paediatric heart failure patients
were similar to those in adults, as no specific clinical in-
formation was available for the paediatric population.
6 Conclusion
PBPK models incorporating hepatic and renal blood flow
changes were developed and evaluated for their ability to
predict carvedilol exposure in both adults in children. The
incorporation of reduced blood flows into the developed
PBPK models significantly improved the prediction of
pharmacokinetic parameters of carvedilol in adult CHF
patients and established a clear relationship between organ
blood flow reductions and the severity of CHF assessed by
the NYHA classification of CHF. The predictions in pae-
diatric patients with CHF were not improved with reduc-
tions in organ blood flows, and it was hypothesized that the
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paediatric system for assessing the severity of heart failure
(the Ross score) was not as well correlated with the organ
blood flow reductions occurring in the disease as the
NYHA classification. Since the majority of the paediatric
patients in the clinical trial were diagnosed with mild heart
failure (with Ross scores of 3–6), it was assumed that the
pathophysiology of the disease in young children is dif-
ferent in mild CHF; this assumption was further strength-
ened when the organ blood flow reductions in children
above 17 years of age, assessed by the NYHA classifica-
tion, resulted in improvements in the predicted pharma-
cokinetic parameters. However, these results cannot be
generalized to all of the paediatric CHF patients, taking
into consideration the small sample size of the paediatric
clinical trial data used for model development and, sec-
ondly, in terms of the severity of disease, the participants
were not evenly distributed throughout the paediatric age
range. In order to draw a definite conclusion regarding the
role of reduced organ blood flows in children, there is a
need for further evaluation with additional clinical phar-
macokinetic data in paediatric patients with different de-
grees of CHF.
Because of the mechanistic nature of the presented
PBPK models, they could be extended to other high-ex-
traction drugs in heart failure patients, or they could serve
as a basis for development of a PBPK model of carvedilol
and similar high-extraction drugs in special populations,
such as geriatric patients, patients with renal insufficiency
or patients with liver failure.
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